• Login
Fintedex — Business, Fincance & Investment News
  • Contact
  • Submit a News Releases
No Result
View All Result
  • Contact
  • Submit a News Releases
No Result
View All Result
Fintedex — Business, Fincance & Investment News
No Result
View All Result
Home Technology

Life sciences news roundup: Adaptive layoffs; Seattle Children’s biotech partnership; and more

Timothy Wilson by Timothy Wilson
13.03.2022
in Technology
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Adaptive’s HQ in Seattle. (GeekWire Photo)

As a bear market takes a bite out of biotech stock values that had soared during the pandemic, some companies are retrenching.

Adaptive Biotechnologies had recently doubled its headcount as it turned to COVID-19 projects, but on Wednesday the Seattle company laid off 12% of its workforce, about 100 employees. The public company is reorganizing to focus on two key areas: immune medicine and “minimal residual disease” cancer detection. Adaptive also hired a new CFO, Tycho Peterson.

“Given current market conditions affecting Adaptive and the biotech industry more broadly, we needed to ensure we had enough flexibility to meet our medium- to long-terms goals,” a spokesperson told GeekWire.

We’ve rounded up other recent life sciences and health tech news in the Pacific Northwest below:

Joyce Yen, head of the UW ADVANCE program. (UW Photo)

  • Joyce Yen recently won a $10,000 U.S. Presidential Award for her mentorship leading the University of Washington ADVANCE Center for Institutional Change. We spoke with her about how to lower barriers to recruiting and retaining women STEM faculty.
  • Seattle Children Therapeutics will advance its BrainChild CAR T cell therapies for central nervous system cancers into phase 2 trials in partnership with Cellevolve. Children’s investigator Dr. Michael Jensen, a co-founder of Umoja Biopharma, will become chair of the San Francisco company’s scientific advisory board, and Seattle Children’s will receive an equity stake.
  • Bothell, Wash.-based Cocrystal Pharma has dosed its first subjects in a phase 1 trial of a broad-spectrum oral antiviral agent for pandemic and seasonal influenza A.
  • Alpine Immune Sciences’ clinical trial for its immune modulator davoceticept, combined with the immune checkpoint drug Keytruda, was put on a partial hold while investigators assess a patient death in the study.   
  • Washington state partners with Seattle-based startup 2morrow to offer its smoking cessation app for free to state residents. A recent study showed the app is being used by a broad range of demographic groups — meanwhile, a measure to ban flavored vape products popular with kids died in the state legislature for the second year in a row.
  • Evergreen Bioscience, an organization working to make Washington state and the Intermountain Northwest a magnet for contract research and manufacturing was awarded $500,000 by Washington state’s Department of Commerce.
  • A new study from the Institute for Health Metrics and Evaluation tallied the overwhelming burden of the pandemic, concluding that 18.2 million people died worldwide from COVID-19 between the start of the pandemic and the end of last year, compared to the 5.94 million deaths officially reported.
  • Here’s a nice profile of a Portland biotech startup, Sparrow Pharmaceuticals, which is testing therapies to soften the effects of excess steroid levels, in phase 2 clinical trials.
  • University of Washington researchers have developed a device to detect the acidity of dental plaque using optical measurements. The readout may tell what area of the tooth is most at risk of developing a cavity, according to a new study.

Editor’s note: Charlotte Schubert previously worked as a science editor and writer at Seattle Children’s Therapeutics.


Previous Post

The Boys season 3 trailer delivers Supe-d up smackdowns and riotous reveals

Next Post

PlayStation State of Play showcases are tepid – and you’d better get used to that

Related Posts

Some Windows updates might actually hurt your security
Technology

Some Windows updates might actually hurt your security

by Timothy Wilson
16.05.2022
It looks like Apple WWDC 2022 will be in-person after all – for some
Technology

It looks like Apple WWDC 2022 will be in-person after all – for some

by Timothy Wilson
16.05.2022
Tech Moves: Longtime Microsoft leader James Phillips leaves Stripe; and more
Technology

Tech Moves: Longtime Microsoft leader James Phillips leaves Stripe; and more

by Timothy Wilson
16.05.2022
Save up to $700 during Nolah Mattress’ Memorial Day Sale
Technology

Save up to $700 during Nolah Mattress’ Memorial Day Sale

by Timothy Wilson
16.05.2022
Report: Apple bringing USB-C to the iPhone but not the iPhone 14
Technology

Report: Apple bringing USB-C to the iPhone but not the iPhone 14

by Timothy Wilson
16.05.2022
Next Post

PlayStation State of Play showcases are tepid - and you’d better get used to that

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Premium Content

: ‘COVID-19 vaccination reduces anxiety and depression symptoms by nearly 30%’

27.12.2021

Dow Jones Newswires: China’s economic activity grew faster than expected in January-February

15.03.2022

Europe Markets: European stocks inch closer to all-time high, inspired by Wall Street optimism

28.12.2021

Browse by Category

  • Business
  • Finance
  • Stock Market
  • Technology
  • Без рубрики

Browse by Tags

Europe Oleg Volin Russia Ukraine

Fintedex delivers real-time news about the financial industry: feature stories, industry developments, opinions plus the latest on people and trends.

Categories

  • Business
  • Finance
  • Stock Market
  • Technology
  • Без рубрики

Browse by Tag

Europe Oleg Volin Russia Ukraine

Recent Posts

  • The Location Guide, Filmmakers for Ukraine and EUFCN join forces for fundraiser at Cannes 2022
  • Free exchange: The world needs a new economic motor. Could India fit the bill?
  • Buttonwood: Why Italy’s borrowing costs are surging once again

© 2021 Fintedex.

No Result
View All Result
  • Contact
  • Submit a News Releases

© 2021 Fintedex.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?